Next-gen cell therapy manufacturing: leveraging flexibility and automation for success
Mar
6
2025
Upcoming webinar

Next-gen cell therapy manufacturing: leveraging flexibility and automation for success

Thursday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET
Sponsor
Next-gen cell therapy manufacturing: leveraging flexibility and automation for success

With the surge in CGT approvals and advancements, the industry faces significant pressure to scale production while maintaining stringent quality and safety standards. Traditional manufacturing methods, often rigid and labor-intensive, are inadequate to handle the complexities and variability inherent in cell therapies. As a result, there is an urgent need for flexible and automated solutions to streamline operations, reduce costs, and expedite time-to-market. This webinar explores advanced technologies and strategies that are pivotal in navigating the dynamic CGT landscape.

  • Critical importance of adaptable solutions: learn how flexible solutions in isolation and activation processes can improve production efficiency, ensuring consistent quality through automation
  • Innovative technologies and optimized workflows: discover how advanced technologies and optimized workflows can shorten manufacturing timelines, addressing the critical demand for efficient therapies
  • Modular approach for enhanced flexibility: learn how a modular approach can enhance flexibility, and improve process optimization, while upholding high standards of quality and adaptability
  • Next level automation CGT manufacturing: flexible integration - The session will explore how flexible automation solutions integrate seamlessly with robotics platforms, fostering an ecosystem of proven tools and technologies. This capability empowers therapy companies to scale their operations efficiently without modifying existing processes
Fred Parietti
Fred Parietti
Co-founder and CEO at Multiply labs

Fred holds a PhD in robotics from MIT and has extensive experience in the design of autonomous robotic systems (awarded with the MIT Mechanical Engineering De Florez Design Award). Before MIT, Fred worked on advanced robotics at Carnegie Mellon University, the Polytechnic University of Milan (Italy) and ETH Zurich (Switzerland). Fred has authored or co-authored 16 peer-reviewed scientific publications, which have been cited more than 1,500 times. He is also a co-inventor in 10 patents and patent applications.

David Shaw
David Shaw
Senior Director and Head of Cell Therapy Engineering and Process Development at Genentech, Inc.

David is currently Head of Cell Therapy Engineering and Process Development at Genentech, Inc. The group is responsible for developing cell therapy processes to support clinical manufacturing of T cell therapies and stem cell therapies. The group collaborates with external partners, CDMO partners and internal Research groups to enable the cell therapy portfolio. David has 24 years of service at Genentech/Roche with 7 years in Cell Therapy Process Development, 8 years in CHO Cell Line Technology Development and 9 years as Head of Molecular Biology and Protein Sciences at Roche Palo Alto. Prior to joining Genentech/Roche, David was a Research Professor at the South Carolina Cancer Center researching retroviral gene therapy to alleviate the myelosuppressive side-effects of chemotherapy. David has a PhD in Biochemistry and Molecular Biology from the University of South Carolina and a BSc in Biochemistry from the University of British Columbia.

Carl Dargitz
Carl Dargitz
Senior Manager, Research and Development at Thermo Fisher Scientific

Carl Dargitz is a Senior Manager in the Cell & Gene Therapy Platforms R&D group and has been developing cell therapy instrumentation at Thermo Fisher Scientific for the past 5 years. Previously, he developed reprogramming and characterization assays for PSCs and immune cells at Thermo Fisher. Before joining Thermo Fisher, he worked at the Salk Institute for Biological Studies at the stem cell core facility managing the core’s reprogramming and characterization services. He received his M.S. from California Polytechnic State University, San Luis Obispo in Biomedical Engineering with a specialization in stem cell research.